Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10015059HBVENSG00000117013.17protein_codingKCNQ4NoNo9132P56696
TVIS10025811HBVENSG00000117013.17protein_codingKCNQ4NoNo9132P56696
TVIS20016304HPVENSG00000117013.17protein_codingKCNQ4NoNo9132P56696
TVIS20047281HPVENSG00000117013.17protein_codingKCNQ4NoNo9132P56696
TVIS20016049HPVENSG00000117013.17protein_codingKCNQ4NoNo9132P56696
TVIS20047292HPVENSG00000117013.17protein_codingKCNQ4NoNo9132P56696
TVIS20033048HPVENSG00000117013.17protein_codingKCNQ4NoNo9132P56696
TCGA Plot Options
Drug Information
GeneKCNQ4
DrugBank IDDB04953
Drug NameEzogabine
Target IDBE0002399
UniProt IDP56696
Regulation Type
PubMed IDs17184917; 11378159; 16713428
CitationsHirano K, Kuratani K, Fujiyoshi M, Tashiro N, Hayashi E, Kinoshita M: Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice. Neurosci Lett. 2007 Feb 14;413(2):159-62. Epub 2006 Dec 20.@@Schroder RL, Jespersen T, Christophersen P, Strobaek D, Jensen BS, Olesen SP: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology. 2001 Jun;40(7):888-98.@@Borlak J, Gasparic A, Locher M, Schupke H, Hermann R: N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism. 2006 Jun;55(6):711-21.
GroupsApproved; Investigational
Direct ClassificationPhenylbenzamines
SMILESCCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
Pathways
PharmGKBPA144997862
ChEMBLCHEMBL41355